

Bipolar Disorder Ups Risk for Lipid Disorders

BY DAMIAN McNAMARA

HOLLYWOOD, FLA. — Bipolar disorder is an independent risk factor for lipid disorders among patients without other known risk factors, according to a large, retrospective, managed care claims database study.

Dr. Quinton E. Moss and his associates also found the association between bipolar disorder and elevated risk remained after they controlled for current use of antipsychotic and lipid-lowering medications. This finding was important because treatments for bipolar disorder, particularly some atypical antipsychotics, can increase lipid abnormalities, he said in an interview at his poster at a meeting of the New Clinical Drug Evaluation Unit sponsored by the National Institute of Mental Health.

Age also played a role, with the risk for



These findings support screening all patients with bipolar disorder for lipid abnormalities.

DR. MOSS

lipid disorders being greatest among bipolar patients in their 20s and 30s. This means the increased risk for dyslipidemia, hypercholesterolemia, or hypertriglyceridemia was independent of lipid changes typically associated with aging, said Dr. Moss, of i3 Research in Basking Ridge, N.J.

It is widely accepted that there is a greater risk of metabolic syndrome and cardiovascular disease among people with bipolar disorder, Dr. Moss said (Ann. Clin. Psychiatry 2008;20:131-7).

He and his colleagues studied de-identified claims from a large U.S. health insurer. They compared 33,019 enrollees who had bipolar disorder and a diagnosis of a lipid disorder, thyroid disorder, or diabetes with an additional 1 million controls with no Axis I mood or psychosis diagnoses.

Patients were aged 20-55 years (mean age, 39 years in both groups). Men comprised 35% of the bipolar disorder cohort and 52% of controls.

Patients with bipolar disorder and no comorbid thyroid disease or diabetes had a significantly increased likelihood of having lipid disorders (odds ratios ranged from 1.85 to 3.07). But the bipolar disorder and lipid disorder association was no longer significant if either comorbidity was present (OR range, 0.51-1.27).

Because some medication use can alter lipid levels (Neuropsychobiology 2006;53:108-12), Dr. Moss and his associates performed a subanalysis that excluded 31% of the bipolar sample taking an antipsychotic agent and the 13% taking a lipid-lowering drug.

“Looking at those who have not been treated with an atypical antipsychotic or those who have not received a lipid-low-

ering agent—we still saw a relationship”

Bipolar patients not taking these medications but who had concomitant thyroid disorder or diabetes were not significantly more likely to have a lipid disorder, with the exception of men aged 30-34 years or 40-55 years and women aged 45-55 years.

“Folks who have bipolar disorder are being screened for lipid disorders before [being prescribed] an atypical antipsy-

chotic, supposedly,” Dr. Moss said. “But there is a group with bipolar disorder not about to be treated who have an increased risk. For example, two-thirds in this study were not being treated, and their risk needs to be evaluated.”

These findings support screening all patients with bipolar disorder for lipid abnormalities, Dr. Moss said.

Regardless of sex, the odds ratio was higher if patients were aged 20-39 years

versus the older age groups. Again, this applied only to patients without one of the comorbidities. There was no significant increased risk by age if one of the comorbidities was present, except among men aged 30-34 years and 50-55 years.

The retrospective study design was a limitation, Dr. Moss said. Also, he did not assess data based on ethnicity or complete medical history, two factors he hopes to address in future research. ■



Treat your patient. Treat yourself.

Register Now for the Fifth Annual Chicago Supportive Oncology Conference

Gain important insight about practical management issues in palliative and supportive care. Learn to:

- ▶ Identify and treat depression and other psychiatric conditions in the patient with cancer
- ▶ Identify cancer survivors at risk for anorexia, cachexia, and other nutritional deficits and incorporate a nutritional plan into their overall care plan
- ▶ Recognize neurotoxicities associated with cancer treatments and strategies for management
- ▶ Describe and address issues in cancer pain management, including management of addictive disease and hyperalgesia and opioid-induced pain
- ▶ Summarize the role of complementary therapies in supportive cancer care, particularly acupuncture and mind-body interventions
- ▶ Explain the effects of cancer treatments on sexuality and fertility and the current approaches for their management
- ▶ Provide mentorship for colleagues in integrating supportive and palliative care into daily clinical practice
- ▶ Identify effective strategies to improve communication issues surrounding the cancer diagnosis, including prognosis, talking with children, and cultural sensitivity
- ▶ Describe palliative measures in advanced disease, specifically lung cancer and liver metastases
- ▶ Integrate evidence-based management of cancer-related mucositis, refractory nausea and vomiting, and diarrhea into a patient's plan of care
- ▶ Evaluate current clinical data on growth factor support, cardiovascular complications with VEGF inhibitors, and skin complications of targeted therapies



Register Now!

www.supportiveoncology.net/chicago